UCLA David Geffen School of Medicine, Center for Health Sciences
Welcome,         Profile    Billing    Logout  
 3 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jung, Brian
A1BC, NCT05297812: Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Active, not recruiting
N/A
286
US
Columbia University, Alpha-1 Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Alpha 1-Antitrypsin Deficiency, Genetic Disease
01/27
01/27
Barjaktarevic, Igor
IKANOS, NCT05970263: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

Withdrawn
4
1000
NA
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator
AstraZeneca, Iqvia Pty Ltd, Premier Inc.
COPD
12/25
12/25
NCT06376994: Multi-Center Clean Air Randomized Controlled Trial in COPD

Recruiting
3
770
US
Air cleaner, Sham air cleaner
JHSPH Center for Clinical Trials, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease (COPD)
09/27
09/28
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RARICO, NCT04315558: Revefenacin in Acute Respiratory Insufficiency in COPD

Recruiting
2
21
US
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
University of California, Los Angeles, Theravance Biopharma, Mylan Pharmaceuticals Inc
COPD, Acute Respiratory Failure
04/25
06/25
ATALANTa, NCT03679598: Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Hourglass Jul 2021 - Dec 2021 : From ATALANTA trial for alpha-1 antitrypsin deficiency
Completed
2
63
US
Alvelestat (MPH966), Placebo
University of Alabama at Birmingham, National Institutes of Health (NIH), Mereo BioPharma, National Center for Advancing Translational Sciences (NCATS)
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
11/23
12/23
DEPTH, NCT05382208: Doxycycline for Emphysema in People Living With HIV (The Trial)

Recruiting
2
250
US
Doxycycline, Placebo
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan
Emphysema, HIV
02/27
02/27
NCT04722887: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Recruiting
1/2
16
US
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human), Prolastin®-C Liquid
Grifols Therapeutics LLC
Alpha1-Antitrypsin Deficiency
03/25
03/25
ILAN, NCT05880836: In Line Aerosol Nebulization With High Flow

Recruiting
N/A
40
US
nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen, standard jet nebulization (SJN) with face mask
University of California, Los Angeles, Aerogen
Hypoxemic Respiratory Failure, Airway Obstruction
12/24
12/24
DLP-LHC, NCT06177717: Deep Functional Phenotyping of the ALA Lung Health Cohort

Recruiting
N/A
1000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, University of Vermont
Lung Diseases
07/26
07/26
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
SPIROMICS, NCT01969344: Study of COPD Subgroups and Biomarkers

Active, not recruiting
N/A
2981
US
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI), COPD Foundation, Columbia University, Johns Hopkins University, National Jewish Health, Temple University, University of Alabama at Birmingham, University of California, Los Angeles, University of California, San Francisco, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University
COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
12/30
12/30
SOURCE, NCT05033990: SPIROMICS Study of Early COPD Progression

Recruiting
N/A
1000
US
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina, Chapel Hill, Columbia University, Johns Hopkins University, National Jewish Health, University of Alabama at Birmingham, University of California, Los Angeles, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University Health Sciences, Temple University, University of California, San Francisco, COPD Foundation, Mayo Clinic
COPD, Early-Onset
01/25
04/25
NCT06505603: PiMZ Longitudinal Cohort (PiMZ Logic)

Not yet recruiting
N/A
80
US
Columbia University, Alpha-1 Foundation
Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
02/29
02/29
A1BC, NCT05297812: Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Active, not recruiting
N/A
286
US
Columbia University, Alpha-1 Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Alpha 1-Antitrypsin Deficiency, Genetic Disease
01/27
01/27
Adams, Brad
No trials found
Villarreal, Miguel
No trials found

Download Options